Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case

Especially in western civilizations, immune diseases that are driven by innocuous (auto- or allo-) antigens are gradually evolving to become pandemic threats. A particularly poignant example is type 1 diabetes, where young children are confronted with the perspective and consequences of total pancreatic β-cell destruction. Along these disquieting observations we find ourselves equipped with impressively accumulating molecular immunological knowledge on the ins and outs of these pathologies. Often, however, it is difficult to translate this wealth into efficacious medicines. The molecular understanding, the concept of oral tolerance induction, the benefit of using recombinant Lactococcus lactis therein and recent openings towards their clinical use may well enable turning all colors to their appropriate fields on this Rubik's cube.

• Publication year

  2014

• Venue

  Microbial Cell Factories

• Publication date

  2014-08-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/1475-2859-13-S1-S11PMID 25185797PMCID 4155828
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of low‐dose otelixizumab anti‐CD3 monoclonal antibody in preserving C‐peptide secretion in adolescent type 1 diabetes: DEFEND‐2, a randomized, placebo‐controlled, double‐blind, multi‐centre study

  2014cited by this paper
• Oral Delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by Lactococcus lactis Reverses Diabetes in Recent-Onset NOD Mice

  2014cited by this paper
• Immune Intervention for Type 1 Diabetes, 2012–2013

  2014cited by this paper
• Phase 1b, multicenter, single blinded, placebo‐controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy

  2013influential reference
• Hsp65-producing Lactococcus lactis prevents experimental autoimmune encephalomyelitis in mice by inducing CD4+LAP+ regulatory T cells.

  2013cited by this paper
• Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial

  2013cited by this paper
• Expression of the immunoreactive buckwheat major allergenic storage protein in Lactococcus lactis

  2013cited by this paper
• Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes

  2013cited by this paper
• Vaccination with IA-2 autoantigen can prevent late prediabetic nonobese diabetic mice from developing diabetes mellitus.

  2012cited by this paper
• Lactococcus lactis-based vaccines from laboratory bench to human use: an overview.

  2012cited by this paper
• The structure of the extracellular teichoic acids from the allergy-protective bacterium Lactococcus lactis G121

  2012cited by this paper
• GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.

  2012cited by this paper
• Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice.

  2012cited by this paper
• Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop.

  2012cited by this paper
• Cyclosporine: A Review

  2012cited by this paper
• Food-Grade Bacteria Expressing Elafin Protect Against Inflammation and Restore Colon Homeostasis

  2012cited by this paper
• Lactococcus lactis NCC 2287 Alleviates Food Allergic Manifestations in Sensitized Mice by Reducing IL-13 Expression Specifically in the Ileum

  2011cited by this paper
• Epidemiology: Racing against the flu

  2011cited by this paper
• Gut-tropic T cells that express integrin α4β7 and CCR9 are required for induction of oral immune tolerance in mice.

  2011cited by this paper
• Oral administration of Lactococcus lactis delivered heat shock protein 65 attenuates atherosclerosis in low-density lipoprotein receptor-deficient mice.

  2011cited by this paper
• Prophylaxis of experimentally induced ovomucoid allergy in neonatal pigs using Lactococcus lactis.

  2011cited by this paper
• Cytokine-inducing lipoteichoic acids of the allergy-protective bacterium Lactococcus lactis G121 do not activate via Toll-like receptor 2.

  2011cited by this paper
• Lifestyle: When allergies go west

  2011cited by this paper
• Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

  2011cited by this paper
• Anti-CD3 Therapy Promotes Tolerance by Selectively Depleting Pathogenic Cells while Preserving Regulatory T Cells

  2011cited by this paper
• CD4 T cells and their antigens in the pathogenesis of autoimmune diabetes.

  2011cited by this paper
• Oral tolerance

  2011cited by this paper
• Genetics, pathogenesis and clinical interventions in type 1 diabetes

  2010cited by this paper
• Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens

  2010cited by this paper
• Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis

  2010cited by this paper
• Clinically validated approaches to the treatment of autoimmune diseases

  2010cited by this paper
• Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

  2010cited by this paper
• An intranasal administration of Lactococcus lactis strains expressing recombinant interleukin‐10 modulates acute allergic airway inflammation in a murine model

  2010cited by this paper
• Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor–specified peripheral niche constraints

  2010cited by this paper
• The ‘hygiene hypothesis’ for autoimmune and allergic diseases: an update

  2010cited by this paper
• Allergy Therapy by Intranasal Administration with Recombinant Lactococcus lactis Producing Bovine β-Lactoglobulin

  2009cited by this paper
• Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients.

  2009cited by this paper
• Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

  2009cited by this paper
• GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes

  2009cited by this paper
• Induction of Antigen-Specific Tolerance by Oral Administration of Lactococcus lactis Delivered Immunodominant DQ8-Restricted Gliadin Peptide in Sensitized Nonobese Diabetic Ab° Dq8 Transgenic Mice1

  2009cited by this paper
• Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study.

  2009cited by this paper
• Autoimmune mechanisms in type 1 diabetes.

  2008cited by this paper
• Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.

  2008cited by this paper
• Translational Mini‐Review Series on Type 1 Diabetes:
Systematic analysis of T cell epitopes in autoimmune diabetes

  2007cited by this paper
• Intranasal Coadministration of Live Lactococci Producing Interleukin-12 and a Major Cow's Milk Allergen Inhibits Allergic Reaction in Mice

  2007cited by this paper
• Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization.

  2007cited by this paper
• Effects of Intranasal Administration of a Leptin-Secreting Lactococcus lactis Recombinant on Food Intake, Body Weight, and Immune Response of Mice

  2007cited by this paper
• Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.

  2007cited by this paper
• Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys.

  2006cited by this paper
• (How) do aluminium adjuvants work?

  2006cited by this paper
• Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs.

  2006cited by this paper
• Immunomodulatory effects of IL-12 secreted by Lactococcus lactis on Th1/Th2 balance in ovalbumin (OVA)-induced asthma model mice.

  2006cited by this paper
• Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1

  2006cited by this paper
• Oral administration of recombinant Lactococcus lactis expressing bovine β‐lactoglobulin partially prevents mice from sensitization

  2005cited by this paper
• A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes

  2005cited by this paper
• Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.

  2005cited by this paper
• Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

  2005cited by this paper
• Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial.

  2005cited by this paper
• Therapeutic potential of oral tolerance

  2004cited by this paper
• The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both?

  2004cited by this paper
• Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice.

  2004cited by this paper
• Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10

  2003cited by this paper
• Intranasal Immunization with Recombinant Lactococcus lactis Secreting Murine Interleukin-12 Enhances Antigen-Specific Th1 Cytokine Production

  2003cited by this paper
• Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy.

  2003cited by this paper
• TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes

  2003cited by this paper
• Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

  2002cited by this paper
• Mechanisms of stimulation of the immune response by aluminum adjuvants.

  2002cited by this paper
• Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

  2002cited by this paper
• Induction of Mucosal Immune Response after Intranasal or Oral Inoculation of Mice with Lactococcus lactis Producing Bovine Beta-Lactoglobulin

  2001cited by this paper
• Total dose and frequency of administration critically affect success of nasal mucosal tolerance induction

  2001cited by this paper
• Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse.

  2001cited by this paper
• Oral tolerance.

  2000cited by this paper
• In vitro characterization of five humanized OKT3 effector function variant antibodies.

  2000cited by this paper
• Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

  2000cited by this paper
• Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study.

  1999cited by this paper
• Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen.

  1999cited by this paper
• Mucosal Delivery of Murine Interleukin-2 (IL-2) and IL-6 by Recombinant Strains of Lactococcus lactis Coexpressing Antigen and Cytokine

  1998cited by this paper
• Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee.

  1998cited by this paper
• Retardation or Acceleration of Diabetes in NOD/Lt Mice Mediated by Intrathymic Administration of Candidate β-Cell Antigens

  1997cited by this paper
• CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice.

  1997cited by this paper
• Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells.

  1996cited by this paper
• Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes

  1996cited by this paper
• Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23).

  1996cited by this paper
• Relationship of the 37,000- and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512).

  1995cited by this paper
• Prevention of autoimmune diabetes in nonobese diabetic female mice by treatment with recombinant glutamic acid decarboxylase (GAD 65).

  1995cited by this paper
• Secretion of biologically active murine interleukin-2 by Lactococcus lactis subsp. lactis

  1995cited by this paper
• Oral tolerance to myelin basic protein induces regulatory TGF-beta-secreting T cells in Peyer's patches of SJL mice.

  1994cited by this paper
• Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.

  1994cited by this paper
• The generation of a humanized, non‐mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties

  1993cited by this paper
• Follow-up of cyclosporin A treatment in Type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects

  1991cited by this paper
• Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase

  1990cited by this paper
• Limited Duration of Remission of Insulin Dependency in Children With Recent Overt Type I Diabetes Treated With Low-Dose Cyclosporin

  1990cited by this paper
• Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein.

  1988cited by this paper
• Cyclosporin-Induced Remission of IDDM After Early Intervention: Association of 1 yr of Cyclosporin Treatment With Enhanced Insulin Secretion

  1988cited by this paper
• Effects of immunosuppression with cyclosporine in insulin-dependent diabetes mellitus of recent onset: the Canadian open study at 44 months.

  1988cited by this paper
• Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments.

  1987cited by this paper
• Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.

  1986cited by this paper
• Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen.

  1986cited by this paper
• Oral tolerance to ovalbumin in mice: studies of chemically modified and 'biologically filtered' antigen.

  1986cited by this paper
• The influence of intestinal processing on the immunogenicity and molecular size of absorbed, circulating ovalbumin in mice.

  1986cited by this paper

• Interfacial-engineered living drugs with "ON/OFF" switching for oral delivery.

  2024cites this paper
• Heterologous Expression of the Antiviral Lectin Griffithsin in Probiotic Saccharomyces boulardii and In Vitro Characterization of Its Properties

  2024cites this paper
• Engineering Probiotics for Diabetes Management: Advances, Challenges, and Future Directions in Translational Microbiology

  2024cites this paper
• Bacteria-based cancer therapy: Looking forward.

  2024cites this paper
• Engineering Microorganisms for Cancer Immunotherapy

  2024cites this paper
• The Effect of Probiotic Supplementation on Glucolipid Metabolism in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

  2023cites this paper
• Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes

  2022cites this paper
• The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics

  2021cites this paper
• Drug delivery to the inflamed intestinal mucosa- targeting technologies and human cell culture models for better therapies of IBD.

  2021cites this paper
• Recombinant Lactococcus lactis Carrying IL-4 and IL-10 Coding Vectors Protects against Type 1 Diabetes in NOD Mice and Attenuates Insulitis in the STZ-Induced Model

  2021cites this paper
• Live biotherapeutic products: the importance of a defined regulatory framework

  2020cites this paper
• Using probiotics for type 2 diabetes mellitus intervention: Advances, questions, and potential

  2020cites this paper
• Biotechnology of health-promoting bacteria.

  2019cites this paper
• Beneficial Modulation of the Gut Microbiome: Probiotics and Prebiotics

  2019cites this paper
• Lactic Acid Bacteria for Delivery of Endogenous or Engineered Therapeutic Molecules

  2018cites this paper
• Microbial modulation of the gut microbiome for treating autoimmune diseases

  2018cites this paper
• Metabolic Flux Analysis using 13C Isotopes: III. Significance for Systems Biology and Metabolic Engineering

  2017cites this paper
• Next-generation probiotics: the spectrum from probiotics to live biotherapeutics

  2017cites this paper
• Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Diseases

  2017cites this paper
• Recombinant Invasive Lactococcus lactis Carrying a DNA Vaccine Coding the Ag85A Antigen Increases INF-γ, IL-6, and TNF-α Cytokines after Intranasal Immunization

  2017cites this paper
• Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect

  2017cites this paper
• Genome Editing of Food-Grade Lactobacilli To Develop Therapeutic Probiotics

  2017cites this paper
• The Evolution of gene regulation research in Lactococcus lactis

  2017cites this paper
• Efficient evaluation of cellulose digestibility by Trichoderma reesei Rut-C30 cultures in online monitored shake flasks

  2016cites this paper
• Reversal of Diabetes in NOD Mice by Clinical-Grade Proinsulin and IL-10–Secreting Lactococcus lactis in Combination With Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells

  2016cites this paper
• Adsorption and degradation of phenoxyalkanoic acid herbicides in soils: A review

  2016cites this paper
• Intestinal delivery of heterologous peptides with lactobacilli

  2015cites this paper